Intervention to optimize guideline-recommended interdependent care delivery in breast and lung cancers with the 4R Oncology model.

Authors

Raymond Liu

Raymond Liu

Department of Medical Oncology, Kaiser Permanente San Francisco Medical Center, San Francisco, CA

Raymond Liu, Julia R. Trosman, Elizabeth Shurell Linehan, Nancy P. Gordon, Marti Hennings, Henie James, Thea Abbe, Jed Abraham Katzel, Chun Fai Ng, Megumi Tomita, Jeffrey B. Velotta, Lori C. Sakoda, Kimberly Beringer, Arliene Ravelo, Zheng Zhu, Bruce Rapkin, Christine B. Weldon

Organizations

Department of Medical Oncology, Kaiser Permanente San Francisco Medical Center, San Francisco, CA, Northwestern University, Feinberg School of Medicine, Chicago, IL, Kaiser Permanente, San Francisco, CA, Division of Research, Kaiser Permanente Northern California, Oakland, CA, Kaiser Permanente, Modesto, CA, Department of Surgery, The Permanente Medical Group, Modesto, CA, Kaiser Permanente, Walnut Creek, CA, Kaiser Permanente, Stockton, CA, Department of Thoracic Surgery, Kaiser Permanente Oakland Medical Center, Oakland, CA, Genentech Inc, South San Francisco, CA, Albert Einstein College of Medicine, Bronx, NY, Northwestern University Feinberg School of Medicine, Chicago, IL

Research Funding

Pharmaceutical/Biotech Company
Genentech, Inc.

Background: Team-based care improves quality, reduces fragmentation and lowers clinician burnout related to ad hoc care coordination. A key teamwork principle is managing timing and sequence of interdependent care (Vogel JOP 2016). The 4R Oncology model featured by the NCI ASCO Teams initiative fosters effective teamwork by facilitating systematic timing / sequence of interdependent care.1 4R is Right Info / Care / Patient / Time. Using a 4R intervention, a large health system created a high-functioning care team and conducted optimizations of guideline-based interdependent care in breast and lung cancers Oct 2020 - Dec 2021.2 We present results of these optimizations. Methods: We compared data from electronic health record on timing and sequence of care between historical control cohorts of patients who received care pre-4R (breast n=274, lung n=173) to the post-optimization 4R cohorts (breast n=211, lung n=140). Patient and tumor characteristics between control and 4R cohorts in both cancers were similar. Results: Timing and sequence of care for 6 of the 7 breast cancer metrics and all 7 lung cancer metrics was significantly improved between the control and 4R cohorts (Table). Despite significant increase, the rate of timely care for some metrics remained low, such as referrals based on distress screening in breast cancer and palliative care consult in lung cancer. Conclusions: The 4R Oncology model is effective in applying teamwork principles and improving timing and sequence of guideline-based care. Opportunities for further care optimizations exist to expand the 4R benefit to a higher number of patients. A learning system established in our institution will inform iterative optimizations. 1. Trosman JOP 2016. 2. Liu JCOOP 2022.

CancerMetricNCCN GuidelineControl Cohort %4R cohort %
BreastPre-treatment referrals based on distress screeningBreast2354*
Bone density test order for ER+ before endocrine therapyBreast7482*
Genetic test results available before surgeryBreast5761
ECHO for HER2+ within 6 weeks of 1st apptSurvivorship1342*
Oncotype result available before medical oncology appt post-surgeryBreast4069*
Social work contact within 30 days of 1st apptDistress7591*
Formal pre-treatment recommendation for alcohol reductionBreast090*
LungPalliative care consult for stage IV within 6 weeks of 1st apptNSCL1528*
Formal screening, referral for falls, frailty, memory, cognition at 1st apptOlder Adult064*
Formal screening, referral to dentist at 1st apptADA054*
Formal screening, referral to flu, other vaccines at 1st apptInfections044*
PET within 2 weeks of diagnosisNSCL5471*
PDL1 results within 2.5 weeks of diagnosis for advanced stageNSCL5587*
NGS results within 2.5 weeks of obtaining tumor tissueNSCL5980*

* Statistically significant vs control, p<0.1. 1st appt, 1st appointment after diagnosis. NSCL, Non small cell lung. ADA, American Dental Association.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Quality Care Symposium

Session Type

Poster Session

Session Title

Poster Session A

Track

Quality, Safety, and Implementation Science,Cost, Value, and Policy,Patient Experience,Survivorship

Sub Track

Guideline-Concordant Care Initiatives

Citation

JCO Oncol Pract 19, 2023 (suppl 11; abstr 34)

DOI

10.1200/OP.2023.19.11_suppl.34

Abstract #

34

Poster Bd #

B17

Abstract Disclosures

Similar Abstracts

First Author: George Therapondos

Abstract

2023 ASCO Quality Care Symposium

Quality of colorectal and anal cancer care delivered during the COVID pandemic.

First Author: Melanie Lynn Powis

Abstract

2023 ASCO Quality Care Symposium

The use of mobile electronic prescribing to drive quality of oncology care delivery.

First Author: Stephen Speicher